{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:37:33Z","timestamp":1789180653210,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01HL133113"],"award-info":[{"award-number":["R01HL133113"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.blre.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,5]],"date-time":"2017-02-05T20:45:29Z","timestamp":1486327529000},"page":"213-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Complementopathies"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-1005","authenticated-orcid":false,"given":"Andrea C.","family":"Baines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2017.02.003_bb0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ni0708-705","article-title":"Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff","volume":"9","author":"Kaufmann","year":"2008","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1556\/EuJMI.2.2012.2.2","article-title":"The complement system: history, pathways, cascade and inhibitors","volume":"2","author":"Nesargikar","year":"2012","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.blre.2017.02.003_bb0015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2017.02.003_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.blre.2017.02.003_bb0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","article-title":"Interactions between coagulation and complement\u2013their role in inflammation","volume":"34","author":"Oikonomopoulou","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"6","key":"10.1016\/j.blre.2017.02.003_bb0035","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.it.2007.02.006","article-title":"Complement and coagulation: strangers or partners in crime?","volume":"28","author":"Markiewski","year":"2007","journal-title":"Trends Immunol"},{"issue":"9","key":"10.1016\/j.blre.2017.02.003_bb0045","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2017.02.003_bb0050","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0049-3848(16)30365-6","article-title":"Examining coagulation-complement crosstalk: complement activation and thrombosis","volume":"141","author":"Foley","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2017.02.003_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv Immunol"},{"issue":"3","key":"10.1016\/j.blre.2017.02.003_bb0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000467889","article-title":"Biochemistry and biology of anaphylatoxins","volume":"3","author":"Hugli","year":"1986","journal-title":"Complement"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.imbio.2011.07.016","article-title":"The new face of anaphylatoxins in immune regulation","volume":"217","author":"Zhou","year":"2012","journal-title":"Immunobiol"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12026-011-8239-5","article-title":"Membrane attack by complement: the assembly and biology of terminal complement complexes","volume":"51","author":"Tegla","year":"2011","journal-title":"Immunol Res"},{"key":"10.1016\/j.blre.2017.02.003_bb0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0065-2776(08)60868-8","article-title":"Control of the complement system","volume":"61","author":"Liszewski","year":"1996","journal-title":"Adv Immunol"},{"key":"10.1016\/j.blre.2017.02.003_bb0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.iy.09.040191.002243","article-title":"Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster","volume":"9","author":"Liszewski","year":"1991","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"10.1016\/j.blre.2017.02.003_bb0085","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.4049\/jimmunol.169.9.4702","article-title":"Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome","volume":"169","author":"Pangburn","year":"2002","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.blre.2017.02.003_bb0090","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.molimm.2011.04.004","article-title":"Complement factor I in health and disease","volume":"48","author":"Nilsson","year":"2011","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0095","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/eji.200838702","article-title":"Genetic, molecular and functional analyses of complement factor I deficiency","volume":"39","author":"Nilsson","year":"2009","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.blre.2017.02.003_bb0100","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.4049\/jimmunol.0902388","article-title":"MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation","volume":"183","author":"Degn","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2017.02.003_bb0105","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1084\/jem.160.5.1558","article-title":"Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes","volume":"160","author":"Medof","year":"1984","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.blre.2017.02.003_bb0110","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9","volume":"144","author":"Rollins","year":"1990","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.blre.2017.02.003_bb0115","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2009-05-199208","article-title":"Coagulation and innate immune responses: can we view them separately?","volume":"114","author":"Delvaeye","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2017.02.003_bb0120","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.02.003_bb0125","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2013.093161","article-title":"Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry","volume":"99","author":"Schrezenmeier","year":"2014","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.blre.2017.02.003_bb0130","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2017.02.003_bb0135","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM199010253231707","article-title":"Inherited comlete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria","volume":"323","author":"Yamashina","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2012-07-441857","article-title":"CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy","volume":"121","author":"Nevo","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.blre.2017.02.003_bb0150","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Hill","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2017.02.003_bb0155","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.blre.2017.02.003_bb0160","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0165","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1308104","article-title":"Targeted therapy with eculizumab for inherited CD59 deficiency","volume":"370","author":"Hochsmann","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2017.02.003_bb0175","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood-2013-01-481499","article-title":"A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT","volume":"122","author":"Krawitz","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2017.02.003_bb0180","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0190","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12021","article-title":"Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria","volume":"90","author":"DeZern","year":"2013","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0195","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2013.090001","article-title":"Polymorphism of the complement receptor 1 gene correlates with hematological response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Rondelli","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.blre.2017.02.003_bb0200","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2017.02.003_bb0205","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1182\/blood-2009-03-195966","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"113","author":"Brodsky","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2017.02.003_bb0210","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0215","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"issue":"7","key":"10.1016\/j.blre.2017.02.003_bb0225","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0230","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.semnephrol.2010.06.006","article-title":"Genetics and genetic testing in hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura","volume":"30","author":"Noris","year":"2010","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.blre.2014.01.003","article-title":"Diagnosis and management of complement mediated thrombotic microangiopathies","volume":"28","author":"Cataland","year":"2014","journal-title":"Blood Rev"},{"issue":"23","key":"10.1016\/j.blre.2017.02.003_bb0240","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.02.003_bb0245","first-page":"1(2)","article-title":"Typical Hus: evidence of acute phase complement activation from a daycare outbreak","author":"Brady","year":"2016","journal-title":"J Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molimm.2013.11.009","article-title":"Interaction of Shiga toxin 2 with complement regulators of the factor H protein family","volume":"58","author":"Poolpol","year":"2014","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0255","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodriguez de Cordoba","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0260","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.02.003_bb0265","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1469-1809.2011.00671.x","article-title":"Age-related penetrance of hereditary atypical hemolytic uremic syndrome","volume":"75","author":"Sullivan","year":"2011","journal-title":"Ann Hum Genet"},{"issue":"11","key":"10.1016\/j.blre.2017.02.003_bb0270","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jmedgenet-2014-102498","article-title":"Factors determining penetrance in familial atypical haemolytic uraemic syndrome","volume":"51","author":"Sansbury","year":"2014","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.blre.2017.02.003_bb0275","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.blre.2017.02.003_bb0280","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1074\/jbc.M114.630871","article-title":"The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease","volume":"290","author":"Bhattacharjee","year":"2015","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0285","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.blre.2017.02.003_bb0290","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.4049\/jimmunol.169.12.6935","article-title":"Complement C3b\/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H","volume":"169","author":"Hellwage","year":"2002","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.blre.2017.02.003_bb0295","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.molimm.2010.03.007","article-title":"Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d","volume":"47","author":"Bhattacharjee","year":"2010","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1016\/j.blre.2017.02.003_bb0300","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.4049\/jimmunol.1201751","article-title":"Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions","volume":"190","author":"Clark","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nchembio.1696","article-title":"Structural basis for sialic acid-mediated self-recognition by complement factor H","volume":"11","author":"Blaum","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.blre.2017.02.003_bb0310","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s002510050534","article-title":"A radiation hybrid map of complement factor H and factor H-related genes","volume":"49","author":"Diaz-Guillen","year":"1999","journal-title":"Immunogenetics"},{"issue":"3","key":"10.1016\/j.blre.2017.02.003_bb0315","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/humu.9408","article-title":"De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome","volume":"27","author":"Heinen","year":"2006","journal-title":"Hum Mutat"},{"issue":"10","key":"10.1016\/j.blre.2017.02.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030431","article-title":"Atypical haemolytic uraemic syndrome associated with a hybrid complement gene","volume":"3","author":"Venables","year":"2006","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0325","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ndt\/gfq658","article-title":"A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome","volume":"26","author":"Maga","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.blre.2017.02.003_bb0330","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1681\/ASN.2015010100","article-title":"A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H\/complement factor H-related 3 Gene in atypical hemolytic uremic syndrome","volume":"27","author":"Challis","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.blre.2017.02.003_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.blre.2017.02.003_bb0340","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/eji.200939280","article-title":"Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I","volume":"40","author":"Nilsson","year":"2010","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0345","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaime","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2017.02.003_bb0350","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-7-42","article-title":"Complement factor I deficiency: a not so rare immune defect: characterization of new mutations and the first large gene deletion","volume":"7","author":"Alba-Dominguez","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.blre.2017.02.003_bb0355","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.imbio.2016.05.002","article-title":"Chromosomal rearrangement - a rare cause of complement factor I associated atypical haemolytic uraemic syndrome","volume":"221","author":"Gleeson","year":"2016","journal-title":"Immunobiol"},{"issue":"22","key":"10.1016\/j.blre.2017.02.003_bb0360","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9395","key":"10.1016\/j.blre.2017.02.003_bb0365","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"International registry of R, familial HT: familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2017.02.003_bb0370","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40246-015-0029-z","article-title":"Complement regulator CD46: genetic variants and disease associations","volume":"9","author":"Liszewski","year":"2015","journal-title":"Hum Genomics"},{"issue":"9","key":"10.1016\/j.blre.2017.02.003_bb0375","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.4049\/jimmunol.180.9.6385","article-title":"A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity","volume":"180","author":"Blom","year":"2008","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.blre.2017.02.003_bb0380","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1681\/ASN.2013070796","article-title":"Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?","volume":"25","author":"Marinozzi","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.blre.2017.02.003_bb0385","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.blre.2017.02.003_bb0390","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0395","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.imlet.2014.01.014","article-title":"Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome","volume":"160","author":"Jozsi","year":"2014","journal-title":"Immunol Lett"},{"issue":"19","key":"10.1016\/j.blre.2017.02.003_bb0400","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.02.003_bb0405","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"Jozsi","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0410","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.blre.2017.02.003_bb0415","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0420","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"31","key":"10.1016\/j.blre.2017.02.003_bb0425","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004330","article-title":"Can eculizumab be discontinued in aHUS?: case report and review of the literature","volume":"95","author":"Sahutoglu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0430","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9378(16)32330-4","article-title":"Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy","volume":"142","author":"Weinstein","year":"1982","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.blre.2017.02.003_bb0435","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2008.07324.x","article-title":"Advances in understanding of pathogenesis of aHUS and HELLP","volume":"143","author":"Fang","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2017.02.003_bb0440","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome","volume":"44","author":"Vaught","year":"2016","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.blre.2017.02.003_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort","volume":"8","author":"Salmon","year":"2011","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.blre.2017.02.003_bb0450","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","article-title":"Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"112","author":"Fakhouri","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.02.003_bb0455","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.blre.2017.02.003_bb0460","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/AOG.0000000000000140","article-title":"Risk factors, management, and outcomes of hemolysis, elevated liver enzymes, and low platelets syndrome and elevated liver enzymes, low platelets syndrome","volume":"123","author":"Fitzpatrick","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.blre.2017.02.003_bb0465","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ajog.2005.08.044","article-title":"Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child","volume":"195","author":"Martin","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.blre.2017.02.003_bb0470","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"issue":"3","key":"10.1016\/j.blre.2017.02.003_bb0475","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2017.02.003_bb0480","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2017.02.003_bb0485","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2017.02.003_bb0490","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1630056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1630056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T23:03:54Z","timestamp":1692659034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1630056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0268960X1630056X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2017.02.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complementopathies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}